These studies have remarked on the high fidelity of BRAF mutant ctDNA to reflect disease burden and tumor status of patients prior to and during treatment (Ascierto et al., 2013; Girotti et al., 2016; Gray et al., 2015; Knol et al., 2016; Schreuer et al., 2016). This evidence concerns the gene BRAF and neoplasm.